ture. We assumed re-intervention and septicaemia rates of ecAVG were equivalent to standard AVGs. Resource use was based on hospital practice and unit costs from published National Health Service datasets. Results: Over a 6 month period, total treatment costs per patient were £5,882 in the TCVC strategy and £4,954 in the ecAVG strategy, delivering potential savings of £927 per patient. Although ecAVG's had higher procedure and re-intervention costs reflecting longer procedure time and device costs (£3,014 vs £1,836), these were offset by significant reductions in septicaemia treatment costs (£1,322 vs £2,176) and in-patient waiting time bed costs (£619 vs £1,870). ConClusions: Adopting ecAVG's as an alternative to TCVCs can potentially deliver cost savings in this hospital. The two treatment strategies will now be assessed in a RCT.
objeCtives: Budget impact (BIM) analysis of the use of paricalcitol versus standard of care (SOC) for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) considering paricalcitol treatment start in the pre-dialysis phase. Methods: Effects and costs deriving from the use of paracalcitol versus SOC for treatment of SHPT in CKD patients were simulated using a Markov models contemplating the natural history of CKD and introducing the use of parcalcitol treatment from the early stage of kidney disease (CKD3) versus SOC considering the use of comparator only from the dialysis stage. A 5-years horizon and the Italian NHS perspective were used. Epidemiologic and clinical data were derived from literature and other assumptions were discussed with clinicians. Both national tariffs and costs from literature were used upon availability and referred to 2012. One-way sensitivity analyses for model inputs were conducted. Costs and effects were discounted at 3% annum. Results: The use of paricalcitol for the treatment of SHPT was cost-saving for the Italian NHS even starting therapy in the early stage of CKD. In a hypothetical cohort of 1,000 patients per treatment group, the overall direct health costs were 10,181,627 Euro for paricalcitol and 10,816,812 Euro for SOC. Both drug-related and others direct costs were lower for paricalcitol resulting in an overall cost-saving of 1,256 Euro per-patient and stemming from a per-patient increase of drug-related costs of 5,126 Euro and a saving of the others direct costs of 6,382 Euro. ConClusions: Timing paricalcitol treatment from the early stage of CKD could induce a cost-saving for the NHS. Moreover, despite the high acquisition costs for paricalcitol, benefits resulting from an early treatment of SHPT could determine a decrease of the others direct costs exceeding the burden of drug costs. bACkgRound: Clinical studies have shown that treatment of chronic kidney disease patients at predialysis stage (predialysis) with a low protein diet (LPD) and ketoanalogues of essential aminoacids (ketoanalogues) provides clinical and economic benefits. Then, it's actual to define pharmacoeconomic effects of using LPD and ketoanalogues in predialysis patients in Russian Federation (RF). objeCtives: To provide pharmacoeconomic assessment of LPD and ketoanalogues supply of predialysis patients in RF. Methods: Decision tree modelling approach, cost-utility (CUA) and budget impact analyses (BIA) were performed. Direct costs (ketoanalogues, erythropoietin, hemodialysis, peritoneal dialysis, etc.) were considered. Two patients groups were compared in the model: ketoanalogues and LPD was administrated for the first arm in predialysis stage, while second arm started in the model of dialysis patients. Results of retrospective efficacy analysis state, that administration of keto-analogues and LPD delays start of dialysis at least for one year. State utility approach was used for cost-utility analysis. Time horizon of the model was up to 5 years. NHS prices and Sechenov University hospitals price lists were used. Results: The first year annual costs were $38511 per patient for the patients group on dialysis and $13763 for the group of ketoanalogues. The results of BIA have shown, that total cost-saving per patient in the group of ketoanalogues and LPD over 5-year period was $21812 compared with the dialysis group. Cost-utility ratio (CUR) for the ketoanalogues and LPD group varies from $15316 per QALY for the first year to $34673 per QALY over five years, while in the dialysis group CUR ranged from $50051 per QALY in the first year to $45819 per QALY over five years. ConClusions: CUA have shown that treatment of predialysis patients with ketoanalogues and LPD in RF is a preferable technology and provides cost-saving of $21812 over five years per patient. objeCtives: Urinary Incontinence (UI) is associated with several chronic health conditions including arthritis. Literature suggests that arthritis may modify the association between chronic conditions and UI. Little is known about this interaction of arthritis with other chronic diseases and their impact on UI. This study examined these associations. Methods: This was a retrospective case-control study of a 10% random sample of IMS Life Link data from 2001-2011. Subjects were > = 18 years of age and continuously enrolled 18 months pre, and 12 months post their first index diagnosis. UI cases had at least two outpatient or one inpatient and one outpatient claim at least 7 days apart, or one pharmacy claim for a UI drug. Controls without UI had the same eligibility criteria as cases and were matched with cases 3:1 on age, gender and region. Comorbidities are observed in the 12-month preindex period after leaving 6 months buffer time immediately before index diagnosis. Conditional logistic regression (CLR) adjusted for health system variables and other co-morbidities was used to investigate the effect of the interaction between arthritis and other comorbidities on UI. Results: There were 24,499 cases, and 73,497 controls with a mean age of 58.29 years and 69.8% females. Forty percent of cases and 24.8% of controls had arthritis in their pre index period. Arthritis alone was significantly associated with UI alone (aOR = 1.87, p< 0.0001), multiple Sclerosis (MS) alone (aOR = 4.25, p< 0.0001) and cardiovascular diseases (CVD) alone (aOR = 1.32, p< 0.0001). However, the interaction of arthritis and MS (aOR = 7.48, p< 0.0001), and arthritis and CVD (aOR = 2.10, p< 0.0001) increased considerably the odds of developing UI. ConClusions: Compared to arthritis or chronic conditions alone, the combination of arthritis with other chronic conditions significantly increases the risk of having UI.
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PUK7 lEngTh Of sTay and mOrTaliTy in hyPErPhOsPhaTEmia PaTiEnTs adminisTErEd PhOsPhaTE BindErs cOmParEd WiTh maTchEd cOnTrOls
Belk K. W. , Craver C. W. MedAssets, Charlotte, NC, USA objeCtives: Hyperphosphatemia, an electrolyte disorder characterized by elevated levels of phosphate in the blood, is a risk factor for chronic kidney disease (CKD) and associated with increased risk of mortality. In addition to dietary changes phosphate binders (PB) may be administered to hyperphosphatemia patients to reduce phosphate levels. The objective of this study is to evaluate the impact of PB on CKD patients with hyperphosphatemia. Methods: A retrospective, crosssectional analysis was conducted on 70,728 inpatient discharges in the MedAssets health system data diagnosed with CKD and hyperphosphatemia for 2009 through 2013. Cohorts of patients with and without PB were matched on age, sex, principal diagnosis, hospital bed size, region, and teaching status using a propensity score and Greedy matching algorithm. In-hospital mortality and length of stay (LOS) were compared between cohorts using multivariate logistic and negative binomial regression models, respectively, controlling for Deyo-Charlson comorbidity score, complications, and procedures. Results: Of patients diagnosed with hyperphosphatemia approximately 46% were administered PB during their stay. Matching resulted in 11432 patients in each cohort with a mean age of 61 and proportionately more males (54%) than females (46%). Patients receiving PB had higher Deyo-Charlson scores (5.70 vs. 5.46, p< .0001) and higher rates of end-stage renal disease (74.6% vs 44.1%, p< .0001) and hemodialysis (65.4% vs 35.4%, p< .0001). Patients without PB had higher rates of acute kidney failure (48.0% vs 33.7%, p< .0001) and transplants (6.8% vs 2.0%, p< .0001). After adjusting for complications and comorbidities phosphate binder use was associated with 7.7% more inpatient days (IRR = 1.077, p< .0001) and a 28% mortality reduction (OR= 0.718, p< .0001) . ConClusions: After controlling for other variables, CKD patients with hyperphosphatemia receiving PB had lower risk of in-hospital mortality and longer LOS compared to patients without a PB. Further studies should assess post-hospitalization outcomes as well as variation among types of PB. objeCtives: Tunnelled central venous catheters (TCVCs) are frequently used for patients requiring urgent vascular access for haemodialysis (HD), whilst they await definitive access creation, primarily arteriovenous fistula (AVF). TCVCs are associated with significant complications notably higher rates of septicaemia which are costly to treat. Early cannulation arteriovenous grafts (ecAVGs) are a new alternative providing vascular access for HD within 24 hours post implantation. We estimated the potential budget impact in a single hospital of replacing TCVCs with ecAVG's for clinically suitable patients while they awaited a functioning AVF. The analysis was used to understand the potential financial implications of adopting ecAVGs and to inform the decision to conduct a Randomised Controlled Trial (RCT) to study the above hypothesis. Methods: A budget impact model was used to estimate the total costs to the hospital of the two treatment strategies. Costs of procedures, re-interventions and septicaemia were included. Clinical inputs including referral delays for treatment and patient acceptability of ecAVG's, were taken from a 6 month observational study conducted at the hospital, internal audits and published litera-
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